262 related articles for article (PubMed ID: 9252738)
1. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
Jorizzo JL; Magee K; Stewart DM; Lebwohl MG; Rajagopalan R; Brown JJ
Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
[TBL] [Abstract][Full Text] [Related]
2. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
[TBL] [Abstract][Full Text] [Related]
3. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
[TBL] [Abstract][Full Text] [Related]
5. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
Andres P; Poncet M; Farzaneh S; Soto P
J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
[TBL] [Abstract][Full Text] [Related]
6. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
8. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis.
Maloney JM; Morman MR; Stewart DM; Tharp MD; Brown JJ; Rajagopalan R
Int J Dermatol; 1998 Feb; 37(2):142-4. PubMed ID: 9542676
[TBL] [Abstract][Full Text] [Related]
9. The safety of halobetasol 0.05% ointment in the treatment of psoriasis.
Watson WA; Kalb RE; Siskin SB; Freer JP; Krochmal L
Pharmacotherapy; 1990; 10(2):107-11. PubMed ID: 2349135
[TBL] [Abstract][Full Text] [Related]
10. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Breneman D; Fleischer AB; Kaplan D; Lebwohl M; Miller B; Pariser D; Rist T; Swinyer L; Liu Y; Foley V
J Drugs Dermatol; 2005; 4(3):330-6. PubMed ID: 15898289
[TBL] [Abstract][Full Text] [Related]
11. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses.
Gip L; Hamfelt A
Cutis; 1984 Feb; 33(2):215-7, 220-2, 224. PubMed ID: 6365474
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
13. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Guenther L; Tan J; Lynde C; Kerrouche N; Villemagne H;
Cutis; 2010 Jan; 85(1):43-50. PubMed ID: 20184211
[TBL] [Abstract][Full Text] [Related]
14. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
17. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
Bhatia N; Stein Gold L; Kircik LH; Schreiber R
J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate for psoriasis: are ointments really more potent?
Warino L; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
Gottlieb AB; Ford RO; Spellman MC
J Cutan Med Surg; 2003; 7(3):185-92. PubMed ID: 12704534
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis.
James M
Cutis; 2001 Apr; 67(4 Suppl):2-9. PubMed ID: 11338723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
